NeuroVision Inc.
This article was originally published in Start Up
Executive Summary
NeuroVision Inc. is looking behind the eye to correct vision problems. It is targeting the back of the brain with a Web-based, noninvasive, patient-specific treatment designed to re-wire the neural connections responsible for vision. The company will first target adult amblyopia, and then move on to presbyopia, myopia and other visual disorders.
You may also be interested in...
Refractive Surgery
For the ultimate in convenience, hundreds of thousands of nearsighted and farsighted patients are turning to refractive surgery, or surgical vision correction procedures that promise a permanent alternative to glasses. New companies that wish to grab a portion of the $12 billion US market for vision correction are avoiding the crowded and competitive excimer laser business, with technologies that treat patients that LASIK (laser in-situ keratomileusis) doesn't serve well.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.